ArticleVeterinary research communications2026
Genotypic and phenotypic evidence of extended-spectrum β-lactamase and carbapenemase-producing shigatoxigenic and intimin-producing Escherichia coli in diarrheic calves in Bangladesh: A hidden zoonotic and public health risk.
Article in Veterinary research communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Shiga toxin-producing Escherichia coli (STEC) is a pathotype of E. coli associated with a wide variety of diarrhoea in neonatal calves, causing a global economic loss in the dairy industry with significant zoonotic risks via STEC and intimin-producing STEC, resulting in enteric and systemic illness, including diarrhoea, haemorrhagic colitis (HC), and haemolytic uremic syndrome (HUS) in humans. The presence of multidrug-resistant (MDR) STEC in neonatal diarrhoeic calves represents a significant public health concern and limits available therapeutic options. This study investigated the presence of extended-spectrum β-lactamase (ESBL) and carbapenemase-producing STEC isolates and their genotypic combinations of virulence and resistance genes in diarrhoeal calves. A total of 75 rectal swabs from diarrhoeic calves aged ≤ 12 weeks were sampled from three districts of Bangladesh, screened using selective culture and polymerase chain reaction (PCR), followed by phenotypic antimicrobial susceptibility profiling and phenotypic and genotypic screening for ESBL- and carbapenemase-production. The E. coli isolation rate among diarrhoeic calves was 80% (60/75; 95% CI: 69.17-88.35). PCR screening revealed the presence of stx1, stx2, and eae virulence genes, and the prevalence of E. coli isolates harbouring these virulence genes was 13.33% (10/75; 95% CI: 6.5-23.1). The ten virulent isolates included five stx-positive, four stx/eae-positive and one eae-positive E. coli. All the virulent isolates (100%) were resistant to ciprofloxacin and meropenem; however, eight (80%) of the tested isolates were susceptible to gentamycin, and 60% were susceptible to amoxicillin-clavulanate. All virulent E. coli isolates were MDR. We observed that 5 (50%) of the virulent E. coli isolates were ESBL producers, and 7 (70%) were carbapenemase producers. The results for phenotypes and genotypes of ESBL- and carbapenemase-producing strains were not concordant. At least one ESBL gene was present in nine of the ten virulent isolates examined, including four ESBL phenotype-negative isolates. Carbapenemase-producing genotypes were significantly more common in isolates with multiple virulence genes than in those with a single virulence gene (p = 0.001). To the best of our knowledge, this is the first report on ESBL- and carbapenemase-producing MDR STEC in diarrhoeic calves in Bangladesh.
Indexed as
Identifiers
42060047What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.